Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
60–89
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Willingness and ability to provide signed Informed Consent; in addition, at U.S. sites, Health Insurance Portability and Accountability Act (HIPAA) authorization, in other countries, as applicable according to national laws
Well-demarcated area of GA secondary to age-related macular degeneration (AMD) in the absence of choroidal neovascularization (CNV)
You may not be if
History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye
Previous subfoveal focal laser photocoagulation in the study eye
Laser photocoagulation in the study eye
Prior treatment with Visudyne, external-beam radiation therapy, or transpupillary thermotherapy in the study eye
GA in either eye due to causes other than AMD
Diabetic retinopathy in either eye
Active or history of wet AMD in either eye
History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug or that might affect interpretation of the results of the study or that renders the patient at high risk for treatment complications
Active malignancy or history of malignancy within the past 5 years
Previous participation in any studies of investigational drugs within 3 months preceding Day 0
Clareo Health | A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy
